Last Updated: June 24, 2026

EXENATIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Exenatide, and when can generic versions of Exenatide launch?

Exenatide is a drug marketed by Amneal and is included in one NDA.

The generic ingredient in EXENATIDE is exenatide synthetic. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the exenatide synthetic profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Exenatide

A generic version of EXENATIDE was approved as exenatide synthetic by AMNEAL on November 19th, 2024.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for EXENATIDE?
  • What are the global sales for EXENATIDE?
  • What is Average Wholesale Price for EXENATIDE?
Recent Clinical Trials for EXENATIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The First Affiliated Hospital of Henan University of Science and TechnologyEARLY_PHASE1
PegBio Co., Ltd.EARLY_PHASE1
National University of SingaporePHASE2

See all EXENATIDE clinical trials

US Patents and Regulatory Information for EXENATIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal EXENATIDE SYNTHETIC exenatide synthetic INJECTABLE;SUBCUTANEOUS 206697-001 Nov 19, 2024 RX No Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Amneal EXENATIDE SYNTHETIC exenatide synthetic INJECTABLE;SUBCUTANEOUS 206697-002 Nov 19, 2024 RX No Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
DrugChatter Q&A for EXENATIDE

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.